Soru

Zorluk: ZorSchizophrenia and Psychotic Disorders

A psychiatry care team is reviewing the management plans for four distinct patients presenting with psychotic spectrum symptoms. Match each patient's specific clinical scenario to the most appropriate next step in pharmacological management.

  • A 32-year-old with chronic perceptual disturbances who has shown no clinical improvement despite two separate 8-week trials of oral olanzapine and oral aripiprazole at maximum tolerated doses.Initiate clozapine therapy with strict absolute neutrophil count monitoring.
  • A 68-year-old with idiopathic Parkinson disease who recently developed distressing visual hallucinations, which have persisted despite a cautious, neurologist-supervised reduction of carbidopa-levodopa.Initiate therapy with pimavanserin or low-dose quetiapine.
  • A 22-year-old who experienced a first episode of psychotic symptoms lasting exactly 18 days before achieving full remission. He is currently asymptomatic and inquiring about the duration of maintenance therapy.Continue maintenance antipsychotic therapy for 1 to 3 months post-remission, followed by a gradual taper.
  • A 29-year-old brought to the emergency department displaying severe, escalating psychomotor agitation, threatening staff, and actively refusing any oral medications.Administer short-acting intramuscular haloperidol and lorazepam.

Cevap

The optimal management strategies involve matching treatment resistance with clozapine, Parkinson disease psychosis with pimavanserin or quetiapine, a brief psychotic episode with a short 1-to-3-month maintenance followed by a taper, and acute uncooperative agitation with intramuscular haloperidol.
Each clinical scenario presents a specific indication for a specialized pharmacological approach. Treatment-resistant psychosis (failure of at least two antipsychotic trials) uniquely requires clozapine. Psychosis secondary to Parkinson disease requires antipsychotics with weak D2 antagonism (pimavanserin, quetiapine) to circumvent worsening motor symptoms. A brief psychotic episode (lasting less than 1 month) is treated with a short course of maintenance therapy followed by a taper, rather than lifelong treatment. Finally, acute agitation in an uncooperative emergency patient necessitates short-acting intramuscular medications to ensure rapid staff and patient safety.

Adım Adım Çözüm

1
Analyze the first clinical vignette regarding the 32-year-old patient.
Identify that failing two 8-week trials of antipsychotics meets the criteria for treatment-resistant psychosis.
Recognizing treatment resistance dictates the transition to the most effective agent for refractory cases, clozapine.
2
Evaluate the 68-year-old patient with Parkinson disease.
Determine that the patient requires an antipsychotic that will not exacerbate underlying parkinsonism.
Standard high-potency D2 antagonists would worsen motor function; therefore, atypical agents with low D2 affinity like quetiapine or pimavanserin are indicated.
3
Assess the symptom timeline of the 22-year-old patient.
Note the 18-day duration of symptoms, placing the diagnosis strictly under 1 month, indicating a brief psychotic episode.
Accurately diagnosing based on the timeline prevents inappropriate lifelong prescribing, guiding the decision toward a short 1-to-3-month maintenance taper.
4
Address the 29-year-old patient in the emergency setting.
Identify the immediate threat of acute agitation combined with medication refusal.
Ensuring safety requires overriding the oral route with a rapid-acting intramuscular formulation.

Anahtar Kavram

Tailored psychopharmacological management of psychotic disorders based on clinical presentation, timeline, comorbidities, and treatment history.
Tahmini Süre:1m 30s
Bu soruyu puanla